<qa>  What is the primary objective of the study?The primary objective of the study is to evaluate time to progression in eligible patients with cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus when treated with the concomitant chemoradiotherapy regimen of bevacizumab5-fluorouracil 5-FUhydroxyurearadiation therapy B-FHX in comparison to 5-fluorouracil hydroxyurea FHX alone. 